Skip to main content
OpenTrials
Completed

NCT Number: NCT02242565

Safety and Effectiveness of Different ShangRing Device Sizes for Adult Male Circumcision in Lusaka, Zambia

The purpose of this study was to assess the safety, effectiveness and acceptability of providing a reduced number of ShangRing sizes for adult voluntary medical male circumcision (VMMC) within routine service delivery in Lusaka, Zambia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–49 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Chilenje Urban Health Centre, Lusaka, Zambia

Loading trial locations.

About this study

We conducted a randomized controlled trial and enrolled 500 HIV-negative men aged 18-49 years at 3 clinics. Participants were randomized to 1 of 2 study arms (Standard Sizing arm vs Modified Sizing arm) in a 1:1 ratio. All 14 adult ShangRing sizes (40-26 mm inner diameter, each varying by 1 mm) were available in the Standard Sizing arm; the Modified Sizing arm used every other size (40, 38, 36, 34, 32, 30, 28 mm inner diameter). Each participant was scheduled for 2 follow-up visits: the removal visit (day 7 after placement) and the healing check visit (day 42 after placement), when they were evaluated for adverse events (AEs), pain, and healing.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must be aged 18 to 49 years;
  • Must be HIV-uninfected per same-day routine voluntary testing at the clinic;
  • Must be uncircumcised (on examination);
  • Must be in good general health, at the discretion of the clinician;
  • Must be free of genital ulcerations or other visible signs of STI (on examination);
  • Must be able to understand study procedures, and agree to abide by them including the follow-up visit schedule;
  • Must freely consent to participate in the study and sign a written informed consent form;
  • Must provide full contact information including cell phone number, address, and other locator information.

Exclusion criteria

  • Has an active genital infection upon visual inspection;
  • Has an anatomic abnormality (e.g. phimosis or hypospadias) that contraindicates ShangRing MMC;
  • Takes a medication that would be a contraindication for elective surgery, such as an anticoagulant or steroid; or
  • Has a self-reported medical condition that would be a contraindication for elective surgery, e.g. hemophilia, extreme obesity, poorly controlled diabetes, sickle cell anemia
  • Has a self-reported allergy or sensitivity to lidocaine or other local
  • Is not available to be circumcised on the same day as screening.

Treatment and study plan

ShangRing

Device

ShangRing device for male circumcision

Primary outcomes

  1. Percentage and 95% confidence interval of men with at least one moderate or severe adverse event.

    Time frame: 42 days

    To assess the safety of ShangRing procedures when providers choose among 7 adult sizes (reduced-sizes or treatment arm) versus the full range of 14 adult sizes (all-sizes or control arm) during routine service delivery in Lusaka, Zambia.

Secondary outcomes

  1. Percentage of men who cannot be properly fitted with a ShangRing device

    Time frame: 42 days

    Assess the effectiveness of ShangRing procedures in the reduced-sizes arm.

  2. Evaluate the acceptability of ShangRing procedures among participants and providers

    Time frame: 42 days

    Participant acceptability (with procedure and cosmetic appearance), pain, and time to return to normal activity after ShangRing circumcision, overall and in each arm.

    Provider acceptability assessing ease, duration, and complications, and preferences comparing ShangRing with other methods of circumcision, and comparing reduced-sizes with all-sizes provision.

  3. Percentage of men with complete healing at 42 days

    Time frame: Day 42

    Percentage of men with complete healing at 42 days for all study participants, and within each arm of the trial.

Sponsors and collaborators

Lead sponsor

FHI 360

Other

Collaborators

  • Bill and Melinda Gates Foundation
  • Ministry of Health, Zambia

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Sep 17, 2014
Registry last updated
Oct 2, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.